These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26757613)

  • 21. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
    Hodder S; Jayaweera D; Mrus J; Ryan R; Witek J;
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):544-51. PubMed ID: 22206504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety and tolerability of etravirine].
    Portilla J
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():21-6. PubMed ID: 20116624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
    Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
    Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
    Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
    AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
    Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
    Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Tambuyzer L; Thys K; Hoogstoel A; Nijs S; Tomaka F; Opsomer M; De Meyer S; Vingerhoets J
    Antivir Ther; 2016; 21(4):317-27. PubMed ID: 26566161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.
    Potard V; Goujard C; Valantin MA; Lacombe JM; Lahoulou R; Chéret A; Girard PM; Costagliola D;
    BMC Infect Dis; 2018 Jul; 18(1):326. PubMed ID: 29996784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Lazzarin A; Campbell T; Clotet B; Johnson M; Katlama C; Moll A; Towner W; Trottier B; Peeters M; Vingerhoets J; de Smedt G; Baeten B; Beets G; Sinha R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):39-48. PubMed ID: 17617271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
    Tudor-Williams G; Cahn P; Chokephaibulkit K; Fourie J; Karatzios C; Dincq S; Opsomer M; Kakuda TN; Nijs S; Tambuyzer L; Tomaka FL;
    HIV Med; 2014 Oct; 15(9):513-24. PubMed ID: 24589294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
    Monteiro P; Perez I; Laguno M; Martínez-Rebollar M; González-Cordon A; Lonca M; Mallolas J; Blanco JL; Gatell JM; Martínez E
    J Antimicrob Chemother; 2014 Mar; 69(3):742-8. PubMed ID: 24128667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
    MacBrayne CE; Rutstein RM; Wiznia AA; Graham B; Alvero CG; Fairlie L; Lypen K; George KH; Townley E; Moye J; Costello DG; Reding CA; Barroso Hofer C; Crauwels HM; Woot de Trixhe X; Tambuyzer L; Vanveggel S; Opsomer M; Kiser JJ;
    AIDS; 2021 Jul; 35(9):1413-1421. PubMed ID: 33831904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
    Córdova E; Loiza E; Porteiro N; Mingrone H
    Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
    Hill A; Grossman H; Cohen C; Nadler J; Peeters M
    HIV Clin Trials; 2007; 8(2):68-76. PubMed ID: 17507322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.
    Briz V; Palladino C; Navarro M; Jiménez de Ory S; González-Tomé M; León J; Núñez-Cuadros E; de José M; Ramos J; Muñoz-Fernández M
    HIV Med; 2011 Aug; 12(7):442-6. PubMed ID: 21395964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.